Extrachromosomal DNA in Cancer
The objective of the group will be to investigate the formation, maintenance and consequences of extrachromosomal DNA (ecDNA) in cancer using cutting edge single-cell screening and spatial technologies. ecDNA leads to high amplification of oncogenes or genes involved in drug resistance under selective pressures and has a prominent role in cancer heterogeneity. The overarching goal will be to identify druggable targets that reduce ecDNA abundance in cancer – and hence ablating a potent tool of genetic heterogeneity and a powerhorse of drug resistance in cancer.
This research group will start its activity on August 1, 2022. For more information about career opportunities related to this project, visit our Career Space.